Lilly Signs a Worldwide License and Research Agreement with Sitryx to Develop New Immunometabolic Therapies
Shots:
- Sitryx to receive $50M upfront- $10M equity investment- ~820M as development & commercial milestones and royalties on sales of therapies. Lilly to get an exclusive global license to develop and commercialize immunometabolism targeted therapies- including Sitryx's two lead projects
- The companies will collaborate for 5yrs. supporting the development of therapies with Sitryx to be responsible for drug discovery while Lilly to fund and manage the clinical & commercial activities
- The collaboration will evaluate up to four novel preclinical targets identified by Sitryx- leading to potential therapies for autoimmune diseases
Click here to read full press release/ article | Ref: Eli Lilly | Image: Luckystep
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com